Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep;110(9):1468-75.
doi: 10.1111/add.13013.

Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration

David P Kao  1 , Mark C P Haigney  2 , Philip S Mehler  1   3 , Mori J Krantz  1   4
Affiliations

Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration

David P Kao et al. Addiction. 2015 Sep.

Abstract

Aim: To assess the relative frequency of reporting of adverse events involving ventricular arrhythmia, cardiac arrest, corrected QT interval (QTc) prolongation or torsade de pointes to the US Food and Drug Administration (FDA) between buprenorphine and methadone.

Design: Retrospective pharmacoepidemiological study.

Setting: Adverse drug events reported spontaneously to the FDA between 1969 and June 2011 originating in 196 countries (71% events from the United States).

Cases: Adverse event cases mentioning methadone (n = 14 915) or buprenorphine (n = 7283) were evaluated against all other adverse event cases (n = 4 796 017).

Measurements: The primary outcome was the composite of ventricular arrhythmia or cardiac arrest. The secondary outcome was the composite of QTc prolongation or torsade de pointes. The proportional reporting ratio (PRR) was used to identify disproportionate reporting defined as a PRR > 2, χ(2) error > 4, with ≥ 3 cases.

Findings: There were 132 (1.8%) ventricular arrhythmia/cardiac arrest and 19 (0.3%) QTc prolongation/torsade de pointes cases associated with buprenorphine compared with 1729 (11.6%) ventricular arrhythmia/cardiac arrest and 390 (2.6%) QTc prolongation/torsade de pointes cases involving methadone. PRRs associated with buprenorphine were not significant for ventricular arrhythmia/cardiac arrest (1.10, 95%, confidence interval (0.93-1.31, χ(2) = 1.2) or QTc prolongation/torsade de pointes (1.03, 95% CI = 0.66-1.62, χ(2) = 0.01), but were for methadone (7.20, 95% CI = 6.88-7.52, χ(2) = 8027; 10.7, 95% CI = 9.66-11.8, χ(2) = 1538, respectively).

Conclusion: In spontaneously reported adverse events, methadone is associated with disproportionate reporting of cardiac arrhythmias, whereas buprenorphine is not. Although these findings probably reflect clinically relevant differences, a causal connection cannot be presumed and disproportionality analysis cannot quantify absolute risk per treatment episode. Population-based studies to definitively quantify differential incidence rates are warranted.

Keywords: Buprenorphine; QTc prolongation; addiction; methadone; opiate; pharmacotherapy; pharmacovigilance; torsade de pointes.

PubMed Disclaimer

Comment in

References

    1. Substance Abuse and Mental Health Services Administration (SAMHSA) Opiod drugs in maintenance and detoxification treatment of opiate addiction; Proposed modification of dispensing restrictions for buprenorphine and buprenorphine combination as used in approved opioid treatment medications. Federal Register. 2012;77:72752–72761. - PubMed
    1. US Food and Drug Administration. Safety alert for ORLAAM (levomethadyl acetate hydrochloride. [cited 2013, Aug 13];Medwatch. 2003 Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHuma..., archived at http://www.webcitation.org/6VLVuCuUg.
    1. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207. - PMC - PubMed
    1. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11:1–171. iii–iv. - PubMed
    1. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J. 1986;111:1088–1093. - PubMed

Publication types